Evidence map›Paper›PMID 36211341›Full record

ArticleFrontiers in immunology2022

Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance.

Xiao Lin, Yanhong Zheng, Hong Li, Junfeng Lu, Shan Ren, Yisi Liu, Xiaoxiao Wang, Sujun Zheng, Lina Ma, Zhenhuan Cao and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xiao LinFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yanhong ZhengFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Hong LiThird Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Junfeng LuFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Shan RenFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yisi LiuFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xiaoxiao WangFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Sujun ZhengFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Lina MaFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Zhenhuan CaoThird Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xinyue ChenFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing YouAn Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is still lack of reliable predictors for hepatitis B surface antigen (HBsAg) clearance. Recent studies have shown that the levels of large (LHBs) and medium hepatitis B surface proteins (MHBs) are closely related to antiviral efficacy. This study aimed to investigate the possibility of LHB and MHB levels to predict HBsAg clearance. Methods: An inactive HBsAg carriers (IHCs) cohort that had received pegylated interferon (Peg-IFN) treatment was divided into the HBsAg-cleared group (R group) and the HBsAg non-cleared group (NR group) based on whether HBsAg was cleared at 96 weeks. We detected the levels of LHBs and MHBs to evaluate the possibility of predicting HBsAg clearance. Results: There were 39 patients in the R group and 21 in the NR group. The total HBsAg, LHB, and MHB levels at baseline and at 12 weeks were significantly lower in the R group than in the NR group (all p< 0.05). Multivariate logistic regression indicated that LHB and MHB levels at baseline and 12 weeks were independent predictors of HBsAg clearance (OR = 0.435, p = 0.016; OR = 0.136, p = 0.003; OR = 0.137, p = 0.033; OR = 0.049, p = 0.043). The area under the curve (AUC) for the baseline and 12-week LHB and MHB levels was 0.827-0.896, which were greater than that of the total HBsAg level at baseline and 12-week (AUC: 0.654-0.755). Compared with the prediction results of a single indicator, the combination of LHB and MHB levels had better value in predicting HBsAg clearance. The AUCs of combination factor 1, constructed from baseline LHB and MHB, and combination factor 2, constructed from 12-week LHB and MHB, were 0.922 and 0.939, respectively, and the sensitivity (82.05%-100.00%) and specificity (85.71%-100.00%) were both high. The combined indicators based on baseline LHBs ≤ 13.99 ng/mL and MHBs ≤ 7.95 ng/mL predicted HBsAg clearance rate of more than 90%. Conclusion: Baseline and 12-week LHB and MHB levels can predict HBsAg clearance obtained by Peg-IFN therapy in IHCs, and the predictive value is higher than that of the total HBsAg levels.

Indexed as

Hepatitis B, ChronicHepatitis B Surface AntigensAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B virusHumansInterferon-alphaMembrane ProteinsPolyethylene GlycolsAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaMembrane ProteinsPolyethylene GlycolsHBsAg clearanceinactive HBsAg carriersLHBsMHBspegylated interferonpredictor

Identifiers

PMID36211341
PMCPMC9537546
OpenAlexW4296830122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.